| Identification | Back Directory | [Name]
MB-07133 | [CAS]
1190389-15-1 | [Synonyms]
RVT-901
KRP-114V
Vibegron-13C-D4
Vibegron (MK-4618)
(6S)-4,6,7,8-Tetrahydro-N-[4-[[(2S,5R)-5-[(R)-hydroxyphenylmethyl]-2-pyrrolidinyl]methyl]phenyl]-4-oxopyrrolo[1,2-a]pyrimidine-6-carboxamide
Pyrrolo[1,2-a]pyrimidine-6-carboxamide, 4,6,7,8-tetrahydro-N-[4-[[(2S,5R)-5-[(R)-hydroxyphenylmethyl]-2-pyrrolidinyl]methyl]phenyl]-4-oxo-, (6S)- | [Molecular Formula]
C26H28N4O3 | [MDL Number]
MFCD28502057 | [MOL File]
1190389-15-1.mol | [Molecular Weight]
444.53 |
| Chemical Properties | Back Directory | [density ]
1.36±0.1 g/cm3(Predicted) | [storage temp. ]
4°C, away from moisture and light | [form ]
Solid | [pka]
13.55±0.70(Predicted) | [color ]
White to off-white | [InChIKey]
DJXRIQMCROIRCZ-XOEOCAAJSA-N | [SMILES]
C12CC[C@@H](C(NC3=CC=C(C[C@@H]4CC[C@H]([C@H](O)C5=CC=CC=C5)N4)C=C3)=O)N1C(=O)C=CN=2 |
| Hazard Information | Back Directory | [Uses]
Vibegron is a potent and selective β3 Adrenergic receptor agonist for the treatment of overactive bladder. | [Definition]
ChEBI: Vibegron is a pyrrolopyrimidine obtained by formal condensation of the carboxy group of (6S)-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-a]pyrimidine-6-carboxylic acid with the amino group of (R)-[(2R,5S)-5-(4-aminobenzyl)pyrrolidin-2-yl](phenyl)methanol. It is a beta3-adrenergic receptor agonist currently in clinical development for the treatment of patients with overactive bladder. It has a role as a beta-adrenergic agonist. It is a secondary alcohol, a member of pyrrolidines, a member of benzenes, a secondary carboxamide, a pyrrolopyrimidine and a secondary amine. | [in vivo]
Vibegron (1~12 μΜ; i.v.) exhibits dose dependent decreases in micturition pressure and increases in functional bladder capacity[3].
Vibegron (30 mg/kg; p.o.; 4 weeks) upregulates mRNA levels of type 1, type 3 collagen, TGF‐β1, and HIF‐1α[4].
Vibegron (1 and 10 mg/kg; i.v.; interval 30 minutes) (10 mg/kg) in oxo-M-treated rats makes bladder capacity significantly decreased compared with oxo-M-not treated rats (intravesical instillation of vehicle)[5]. | Animal Model: | Rat | | Dosage: | 1~12 μΜ | | Administration: | I.v. | | Result: | Exhibited dose dependent decreases in micturition pressure and increases in functional bladder capacity.
|
| Animal Model: | Female C57BL/6N mice (9 weeks old) | | Dosage: | 30 mg/kg | | Administration: | P.o.; 4 weeks | | Result: | Upregulated mRNA levels of type 1, type 3 collagen, TGF‐β1, and HIF‐1α at 4 weeks.
|
| Animal Model: | Female F344 rats (120–160 g) | | Dosage: | 1 and 10 mg/kg
| | Administration: | I.v.; Interval 30 minutes | | Result: | Vibegron (10 mg/kg) in oxo-M-treated rats made bladder capacity significantly decreased compared with oxo-M-not treated rats (intravesical instillation of vehicle).
|
| [IC 50]
β adrenergic receptor; β3 adrenoceptor: 1.1 nM (EC50) | [storage]
4°C, away from moisture and light |
|
|